Supported by

Stents, scaffolds and DCB

Find all the latest content on stents and scaffolds published on this website.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents, scaffolds and DCB

568 results

1-year SELUTION DeNovo results: drug-eluting balloon strategy vs. systematic drug-eluting stent in de novo coronary disease

29 Oct 2025

Guillaume Bonnet interviews Christian Spaulding about the SELUTION DeNovo Trial he presented at TCT 2025, in San Francisco. 

Prof. Christian Spaulding, principal investigator of the study, discusses the trial design, key outcomes, breaks down the nuances behind the sirolimus DCB strategy versus contemporary DES, and shares insights...

Guillaume Bonnet

Author

Guillaume BONNET

Author

Christian Spaulding
1-year SELUTION DeNovo results: DEB strategy vs. systematic DES in de novo coronary disease

Validation of intravascular ultrasound-defined optimal stent expansion criteria for favorable 1-year clinical outcomes

17 Nov 2025

This individual patient data analysis of the three largest RCTs evaluating IVUS-guided stent optimisation showed that an MSA > 5.5 mm2 was associated with reduced TVF at one year. 

Ruxandra Sava

Reviewer

Ruxandra Sava
Nicola Ryan

Reviewer

Nicola Ryan
Validation of IVUS-defined optimal stent expansion criteria for favorable 1-year clinical outcomes

Ten trials from AHA 2025

12 Nov 2025

Alessandro Sticchi provides us with a curated overview of the late-breaking trials he found most relevant for interventional cardiologists from AHA 2025.

Alessandro Sticchi

Author

Alessandro Sticchi
Ten trials from AHA 2025

1-year SELUTION DeNovo results: what they mean for daily practice

29 Oct 2025

The SELUTION DeNovo trial, presented by Christian Spaulding at TCT 2025, delivers the first head-to-head comparison between a sirolimus DCB strategy and contemporary DES in PCI.

In this review, Salvatore Brugaletta breaks down the 1-year results and what these findings truly mean for everyday lesion-by-lesion decision-making.

Guillaume Bonnet

Author

Guillaume BONNET

Author

Christian Spaulding

Author

Salvatore Brugaletta
1-year SELUTION DeNovo results: what they mean for daily practice

Comparison of drug-coated versus conventional balloons for treatment of side branches of bifurcation lesions: the OCVC-BIF study

29 Oct 2025

Ali Nazmi Calik provides his take on the OCVC-BIF study presented by Takayuki Ishihara at TCT 2025, in San Francisco.

Author

Ali Nazmi Calik
Comparison of drug-coated versus conventional balloons for treatment of side branches of bifurcation lesions: The OCVC-BIF study

Sirolimus-eluting iron bioresorbable scaffold in coronary artery disease: two-year results of IRONMAN-II randomised controlled trial

25 Oct 2025

Alex Sticchi interviews Lei Song on the IRONMAN II trial he presented at TCT 2025, in San Francisco.

Alessandro Sticchi

Author

Alessandro Sticchi
Lei Song

Author

Lei Song
IRONMAN II: 2-year outcomes of sirolimus-eluting bioresorbable scaffolds vs. DES

New DCB indications for everyday practice

14 Oct 2025

Watch this replay with F. Ribichini, M. Götberg, B. Khialani and B. Vaquerizo to Review the newest indications for the use of DCB with a focus on STEMI, CTO, bifurcations and calcified lesions, and so much more!

New DCB indications for everyday practice

Bifurcations and left main interventions

11 Oct 2025 – From AICT-AsiaPCR 2025

Delve into the complexities of bifurcation and left main coronary interventions with this session focusing on challenging cases and advanced techniques. Topics include management of complications during drug-eluting stent deployment, Impella-supported orbital atherectomy in heavily calcified lesions, and PCI in patients with severe comorbidities such as...

Precision in plaque management: hybrid techniques and IVUS imaging for optimal outcomes

11 Oct 2025 – From AICT-AsiaPCR 2025

This session offers an in-depth exploration of precision plaque management strategies through hybrid lesion preparation techniques and advanced intravascular ultrasound (IVUS) imaging. It emphasizes the synergistic use of drug-coated balloons and drug-eluting stents to optimize PCI outcomes. Participants will gain a deeper understanding of how cutting...

Precision in plaque management: hybrid techniques and IVUS imaging for optimal outcomes

The future is now: next-gen resorbable magnesium scaffold

11 Oct 2025 – From AICT-AsiaPCR 2025

This session highlights the emerging role of next-generation resorbable magnesium scaffolds in coronary interventions. It provides detailed insights into the FREESOLVE technology, its clinical applications, and the latest evidence from the BIOMAG-I study with three-year outcomes. Clinical experiences with FREESOLVE are discussed to inform on safety,...